Hoechst Pakistan Limited (PSX:HPL)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
3,977.00
+36.29 (0.92%)
At close: Sep 30, 2025
0.92%
Market Cap38.54B
Revenue (ttm)29.71B
Net Income (ttm)2.37B
Shares Out9.64M
EPS (ttm)246.17
PE Ratio16.23
Forward PEn/a
Dividend135.00 (3.39%)
Ex-Dividend DateAug 22, 2025
Volume83
Average Volume976
Open3,941.10
Previous Close3,940.71
Day's Range3,941.10 - 3,999.99
52-Week Range1,900.10 - 4,290.00
Beta0.26
RSI56.50
Earnings DateOct 27, 2025

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqu... [Read more]

Industry Pharmaceutical Preparations
Founded 1967
Employees 837
Stock Exchange Pakistan Stock Exchange
Ticker Symbol HPL
Full Company Profile

Financial Performance

In 2024, Hoechst Pakistan's revenue was 26.75 billion, an increase of 25.17% compared to the previous year's 21.37 billion. Earnings were 1.86 billion, an increase of 414.72%.

Financial Statements

News

There is no news available yet.